The estimated Net Worth of Albert P Parker is at least $705 Thousand dollars as of 15 February 2023. Mr. Parker owns over 3,173 units of Oncocyte stock worth over $703,756 and over the last 6 years he sold OCX stock worth over $1,713. In addition, he makes $0 as Chief Operating Officer at Oncocyte.
Albert has made over 2 trades of the Oncocyte stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 3,173 units of OCX stock worth $1,713 on 15 February 2023.
The largest trade he's ever made was buying 5,000 units of Oncocyte stock on 3 August 2020 worth over $6,650. On average, Albert trades about 817 units every 93 days since 2019. As of 15 February 2023 he still owns at least 227,018 units of Oncocyte stock.
You can see the complete history of Mr. Parker stock trades at the bottom of the page.
Albert P. Parker J.D. serves as Chief Operating Officer of the Company. Prior to joining Oncocyte, Mr. Parker was the managing shareholder of GC Legal Advisors, a law firm established to provide or supplement in-house legal support on an interim, part-time, or project basis for companies operating across various industries. Mr. Parker also served as Executive Vice President, General Counsel and Corporate Secretary of Sunovion Pharmaceuticals from 2013 to 2014. From 2000-2010, Mr. Parker served in a number of management and legal positions at the Vice President or Senior Vice President and Chief Counsel level at Wyeth Pharmaceuticals (now a part of Pfizer). Before joining Wyeth Pharmaceuticals, Mr. Parker served as an Assistant General Counsel at Warner-Lambert Company, and was a partner in a Philadelphia law firm. Mr. Parker holds a J.D. from the University of Pennsylvania Law School and a B.A. from Pennsylvania State University.
Albert's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA, 19333.
Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin..., and Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Oncocyte executives and other stock owners filed with the SEC include: